Frank Szulzewsky

This study identifies TEAD inhibition as a therapeutic target in meningioma and shows that combining MEK and mTOR inhibition overcomes resistance in resistant lines.

This study identifies MERTK as a therapeutic target in ZFTA-RELA-driven ependymomas through transcriptomic analysis and drug screening.

This paper develops PROTACs to degrade oncogenic TRK fusions, showing improved efficacy compared to traditional inhibitors.

The paper identifies PTEN loss as a driver of aggressive NF2 mutant meningiomas and validates a cross-species model for preclinical testing.

This study investigates how C-terminal fusion partners, specifically TFE3 domains, contribute to the oncogenic activity of YAP1::TFE3 fusion proteins in tumors.

The paper identifies RNA Polymerase II hypertranscription at histone genes in cancer FFPE samples, linking it to tumor progression and aneuploidy.

This study shows ERK signaling promotes resistance to TRK inhibitors in NTRK fusion-driven glioma mouse models and suggests MEK inhibition as a potential combination therapy.

This study combines bulk RNA-Seq datasets to create a transcriptomic landscape of meningiomas, identifies subtypes with distinct biology and prognosis, and provides an interactive tool for outcome prediction.

The paper shows that aggressive high-grade NF2 mutant meningiomas have reduced YAP1 activity due to increased VGLL4 and FAT3/4 expression, linked to higher recurrence risk.

The paper combines five RNA-seq datasets to create a reference landscape of human brain tissues and tumors, enabling comparative gene expression analysis across normal and neoplastic samples.